Literature DB >> 1797320

Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine.

A Vaccari1, M Del Zompo, F Melis, G L Gessa, Z L Rossetti.   

Abstract

The neurotoxin MPP+ potently inhibited the striatal binding of [3H]-tyramine, a putative marker for the vesicular transporter of dopamine, and provoked a massive in vivo release of striatal dopamine. Tetrabenazine, an established ligand for the vesicular catecholamine carrier, potently inhibited [3H]-tyramine binding, tyramine-provoked striatal efflux of dopamine and the fast component of MPP(+)-induced dopamine release. It is concluded that MPP+ in the striatum, besides interacting with additional intracellular targets, avidly binds at a vesicular site functionally involved with the outward transport of dopamine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797320      PMCID: PMC1908230          DOI: 10.1111/j.1476-5381.1991.tb12470.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles.

Authors:  J P Henry; D Scherman
Journal:  Biochem Pharmacol       Date:  1989-08-01       Impact factor: 5.858

2.  Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.

Authors:  J F Reinhard; E J Diliberto; O H Viveros; A J Daniels
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  [3H]tyramine binding: a comparison with neuronal [3H]dopamine uptake and [3H]mazindol binding processes.

Authors:  A Vaccari; G Gessa
Journal:  Neurochem Res       Date:  1989-10       Impact factor: 3.996

4.  [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion binding sites in mouse brain: pharmacological and biological characterization.

Authors:  M Del Zompo; S Ruiu; R Maggio; M P Piccardi; G U Corsini
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

5.  In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: II. Studies using potassium and tyramine.

Authors:  I S Fairbrother; G W Arbuthnott; J S Kelly; S P Butcher
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

6.  High affinity binding of [3H]-tyramine in the central nervous system.

Authors:  A Vaccari
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

7.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

8.  The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+).

Authors:  S Carboni; F Melis; L Pani; M Hadjiconstantinou; Z L Rossetti
Journal:  Neurosci Lett       Date:  1990-09-04       Impact factor: 3.046

9.  MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis.

Authors:  H Rollema; W G Kuhr; G Kranenborg; J De Vries; C Van den Berg
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

10.  Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter.

Authors:  A J Daniels; J F Reinhard
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

  10 in total
  4 in total

1.  Tyramine excites rat subthalamic neurons in vitro by a dopamine-dependent mechanism.

Authors:  Zi-Tao Zhu; Adam C Munhall; Steven W Johnson
Journal:  Neuropharmacology       Date:  2006-12-28       Impact factor: 5.250

2.  Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity.

Authors:  M Del Zompo; M P Piccardi; S Ruiu; M Quartu; G L Gessa; A Vaccari
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

Review 3.  The tyramine binding site in the central nervous system: an overview.

Authors:  A Vaccari
Journal:  Neurochem Res       Date:  1993-08       Impact factor: 3.996

4.  Potent, extra-channel influence of several calcium-channel modulators on striatal binding of [3H]tyramine.

Authors:  A Vaccari; P Saba; G Gessa
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.